Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study found that Chinese patients with alopecia totalis or universalis had an earlier onset, longer disease duration, and more severe quality of life impact compared to those with patchy alopecia areata.

This study found that among Chinese patients with alopecia areata, those with alopecia totalis/universalis had an earlier onset, longer duration, and more severe quality of life impact compared to those with patchy alopecia.

This study observed that Chinese patients with alopecia totalis or universalis had an earlier onset, longer duration, and more severe impact on quality of life compared to those with patchy alopecia areata.

This review examines existing and potential treatments for alopecia areata but does not report new clinical results, emphasizing the need for future therapies that target immune pathways or protect hair follicles from inflammation.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

This article presents a discussion on alopecia areata in infants and concludes that the condition's occurrence in this age group is not as rare as previously thought; it offers no new data.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

This study reported that 45.5% of patients with beard alopecia areata progressed to scalp alopecia areata within at least 12 months, with most cases occurring during the first year.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

In this study, 62.7% of patients with alopecia areata had deficient vitamin D levels, yet there was no significant link between these levels and specific alopecia areata patterns.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

In this study, eight Chinese patients with alopecia areata showed hair regrowth following combination therapy with a nonablative laser and topical minoxidil, with most patients not experiencing relapse after one year, suggesting a promising alternative treatment without significant side effects.

This study found that women with androgenetic alopecia or alopecia areata have significantly lower serum ferritin levels than those without hair loss, suggesting a potential link between these types of alopecia and decreased iron stores.

This article reviews alopecia areata as a chronic autoimmune disease affecting hair follicles and discusses its association with other autoimmune conditions, but provides no new clinical findings.

This case report highlights that new nonscarring alopecia after transplantation may indicate chronic graft-vs-host disease, with dermatologists playing a key role in diagnosis and treatment.

People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.

This review discusses the incidence, demographics, and associated conditions of alopecia areata and provides no new clinical findings.

A man had an unusual type of hair loss that didn't match known patterns and didn't improve with treatment.

This case report describes a 22-month-old with alopecia universalis who showed improved hair growth after receiving combination therapy with minoxidil, corticosteroids, and excimer laser.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

This meta-analysis found that patients with alopecia areata, especially those with more severe forms like alopecia totalis or universalis, may have an increased risk of cardiovascular disease, suggesting a potential link between the systemic inflammation in AA and cardiovascular risk.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This report describes a case where treatment with the JAK inhibitor ruxolitinib significantly improved beard growth in a patient with severe alopecia areata, emphasizing its potential benefits for populations where beard hair holds cultural significance.